Literature DB >> 25128058

Improving the contribution of regulatory assessment reports to health technology assessments--a collaboration between the European Medicines Agency and the European network for Health Technology Assessment.

Michael Berntgen1, Anne Gourvil2, Mira Pavlovic2, Wim Goettsch3, Hans-Georg Eichler4, Finn Børlum Kristensen5.   

Abstract

In response to a recommendation from the Pharmaceutical Forum, the European Medicines Agency and the European network for Health Technology Assessment initiated a collaboration with the aim to improve the contribution regulatory assessment reports can make to the assessment of relative effectiveness of medicinal products by health technology assessment bodies. This collaboration on improving European Public Assessment Reports (EPARs) started in February 2010 and was performed over 2 years. As a result, the templates for preparing EPARs were revised to better address the needs of heath technology organizations. The better understanding of information needs was a key outcome of the collaboration. To ascertain whether these template changes led to the inclusion of relevant information, a review of a small set of EPARs for recently approved medicinal products was carried out in parallel by both the European network for Health Technology Assessment and the European Medicines Agency. This report provides an account of this project on improving EPARs, which is part of the ongoing dialogue between regulators and health technology assessment bodies on a European level to support policymaker decisions in the future.
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Keywords:  European Medicines Agency (EMA); European Public Assessment Reports (EPARs); European network for Health Technology Assessment (EUnetHTA); relative effectiveness assessment

Mesh:

Year:  2014        PMID: 25128058     DOI: 10.1016/j.jval.2014.04.006

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  11 in total

Review 1.  Bringing in health technology assessment and cost-effectiveness considerations at an early stage of drug development.

Authors:  Bengt Jönsson
Journal:  Mol Oncol       Date:  2014-10-23       Impact factor: 6.603

2.  Integrating health technology assessment requirements in the clinical development of medicines: the experience from NICE scientific advice.

Authors:  François Maignen; Leeza Osipenko; Pilar Pinilla-Dominguez; Emily Crowe
Journal:  Eur J Clin Pharmacol       Date:  2016-12-10       Impact factor: 2.953

3.  Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.

Authors:  Lada Leyens; Angela Brand
Journal:  Public Health Genomics       Date:  2016-06-01       Impact factor: 2.000

4.  Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.

Authors:  Michael Köhler; Susanne Haag; Katharina Biester; Anne Catharina Brockhaus; Natalie McGauran; Ulrich Grouven; Heike Kölsch; Ulrike Seay; Helmut Hörn; Gregor Moritz; Kerstin Staeck; Beate Wieseler
Journal:  BMJ       Date:  2015-02-26

5.  How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice.

Authors:  Giovanni Tafuri; Margherita Pagnini; Jane Moseley; Marco Massari; Frank Petavy; Antje Behring; Arantxa Catalan; Elangovan Gajraj; Niklas Hedberg; Mercè Obach; Leeza Osipenko; Pierluigi Russo; Marc Van De Casteele; Eva-Maria Zebedin; Guido Rasi; Spiros Vamvakas
Journal:  Br J Clin Pharmacol       Date:  2016-07-01       Impact factor: 4.335

6.  Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.

Authors:  Huseyin Naci; Courtney Davis; Jelena Savović; Julian P T Higgins; Jonathan A C Sterne; Bishal Gyawali; Xochitl Romo-Sandoval; Nicola Handley; Christopher M Booth
Journal:  BMJ       Date:  2019-09-18

7.  Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision-making of oncology medicines.

Authors:  Rachel R J Kalf; Rick A Vreman; Diana M J Delnoij; Marcel L Bouvy; Wim G Goettsch
Journal:  Pharmacol Res Perspect       Date:  2021-04

8.  Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.

Authors:  Lourens T Bloem; Rick A Vreman; Niels W L Peeters; Jarno Hoekman; Menno E van der Elst; Hubert G M Leufkens; Olaf H Klungel; Wim G Goettsch; Aukje K Mantel-Teeuwisse
Journal:  Clin Transl Sci       Date:  2021-05-01       Impact factor: 4.689

9.  Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching.

Authors:  Don Husereau; Brian Feagan; Carl Selya-Hammer
Journal:  Appl Health Econ Health Policy       Date:  2018-06       Impact factor: 2.561

Review 10.  Improving Interactions Between Health Technology Assessment Bodies and Regulatory Agencies: A Systematic Review and Cross-Sectional Survey on Processes, Progress, Outcomes, and Challenges.

Authors:  Richard Ofori-Asenso; Christine E Hallgreen; Marie Louise De Bruin
Journal:  Front Med (Lausanne)       Date:  2020-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.